BSEM BioStem Technologies Inc

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

The presentation will be webcast at 1:30 PM ET on April 10, 2025

POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting investor meetings during the conference.

BioStem Technologies Presentation Access:

  • Presenter: Jason Matuszewski, Chief Executive Officer
  • Date: Thursday, April 10, 2025
  • Time: 1:30 PM ET
  • Webcast Link & Archive:
  • 1-on-1 Meeting Request:

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign-up to the Company’s email distribution list , and follow us on and .

About BioStem Technologies, Inc. (OTC: BSEM):

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

For more information visit and follow us on and .

BioStem Technologies, Inc.

Phone: 954-380-8342

Website: E-Mail: X: Facebook:

Investor Relations

Adam Holdsworth

917-497-9287



EN
27/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies to Present at the 25th Annual Needham Virtual Hea...

BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference POMPANO BEACH, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference. BioStem’s management is scheduled to present on Monday, April 13, 2026, at 8:45 am ET. Interested parties may access live and archived webcasts of the presentations on the “invest...

 PRESS RELEASE

BioStem Technologies Announces the Publication of its Audited Financia...

BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 The Company continues its progression towards a Nasdaq uplisting POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has filed its audited consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2025. The financial statements are available for review in t...

 PRESS RELEASE

BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financi...

BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial and Business Highlights Generated net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97%Completed the acquisition of the BioTissue Holdings Inc. surgical and ...

 PRESS RELEASE

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee...

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board Pompano Beach, FL, March 23, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee, effective March 18, 2026.   Jodi Ungrodt ...

 PRESS RELEASE

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee...

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board POMPANO BEACH, Fla., March 23, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee, effective March 18, 2026.   Ungro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch